S-1: Calidi Biotherapeutics Launches Public Offering Amid Losses

Calidi Biotherapeutics, a clinical-stage biotechnology company, is offering up to 1.2 million common stock units and pre-funded warrant units to raise approximately $5.1 million in net proceeds, as it faces recurring losses and substantial doubt about its ability to continue as a going concern.

Summary

• Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing genetic medicines and genetically-engineered oncolytic viruses for oncology.
• The company is offering up to 1,197,605 common stock units and pre-funded warrant units, with an assumed public offering price of $5.01 per common stock unit.
• The offering is expected to generate approximately $5.1 million in net proceeds, or $5.9 million if the underwriters' over-allotment option is fully exercised.
• The company reported net losses of $10.8 million for the six months ended June 30, 2025, and $22.2 million and $29.2 million for the years ended December 31, 2024, and 2023, respectively.
• As of June 30, 2025, the company had an accumulated deficit of $132.4 million and cash of $5.3 million.
• Management believes existing cash and anticipated proceeds from this offering will meet capital needs for the next 6 months, but substantial additional funding is required beyond that.
• The company's independent registered public accounting firm's report for 2024 and 2023 included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• A 1-for-12 reverse stock split was effective on August 4, 2025, following a 1-for-10 reverse stock split effective July 15, 2024.
• The company's common stock is listed on the NYSE American under the symbol CLDI, with a closing price of $5.01 per share on August 8, 2025.
• Outstanding shares of common stock as of August 8, 2025, were 3,426,446 (excluding 150,000 non-voting shares held in escrow).

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial position, marked by significant recurring losses, a large accumulated deficit, and explicit 'going concern' doubt. While it has promising early-stage clinical programs and a Fast Track designation, its immediate liquidity is severely constrained, requiring frequent capital raises that lead to substantial shareholder dilution. The reliance on future financing for continued operations, coupled with ongoing legal proceedings and a volatile stock price, presents an extremely high-risk investment profile. The positive clinical developments are overshadowed by the severe financial instability.

Positives

• CLD-201 (SuperNova) was granted Fast Track Designation by the U.S. FDA in July 2025 for the treatment of soft tissue sarcoma, potentially expediting its development and review.
• The company's RedTail platform, designed for systemic delivery of oncolytic viruses and genetic medicines to tumor sites, is expected to open an IND by the end of 2026 with its first compound, CLD-401.
• The SuperNova and NeuroNova platforms use stem cells to protect oncolytic viruses from immune clearance and enhance viral amplification at tumor sites, showing substantial preclinical benefit.
• The company has a diversified pipeline with programs targeting metastatic solid tumors (RedTail), solid tumors like breast cancer, sarcoma, and head and neck cancer (SuperNova), and high-grade glioma (NeuroNova).
• The company has secured $4.6 million in gross proceeds from the exercise of existing warrants at a reduced exercise price in July 2025, demonstrating some investor participation.
• The company has a strong intellectual property portfolio with issued patents in multiple jurisdictions covering its technology platforms and product candidates, with some expiring as late as 2045.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales to date.
• Significant operating losses have been incurred since inception, with an accumulated deficit of $132.4 million as of June 30, 2025.
• The company needs substantial additional funding and its ability to continue as a going concern is in substantial doubt, as indicated by management and the independent auditor.
• The current offering's net proceeds of $5.1 million are estimated to meet capital needs for only the next 6 months, highlighting a persistent funding gap.
• The company's product candidates are based on novel approaches, which creates significant challenges in manufacturing, regulatory approval, and market acceptance, and makes development time and cost difficult to predict.
• The sale of additional equity or convertible securities, including this offering, will result in immediate and substantial dilution for existing stockholders.
• The company's stock price is likely to be highly volatile, and there is no established public trading market for the Pre-Funded Warrants or Common Warrants, limiting their liquidity.
• The company faces substantial competition from major pharmaceutical and biotechnology companies with significantly greater financial resources.
• The company has outstanding debt obligations totaling $1.42 million as of June 30, 2025, including related party term notes and a promissory note.
• The company is involved in several legal proceedings, including a complaint from a former executive seeking $0.6 million in damages and a securities fraud complaint, with uncertain outcomes.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history and no product sales revenue to date, making its future success highly speculative.
• Significant operating losses have been incurred since inception, and continued losses are anticipated for the foreseeable future, impacting stockholders' deficit and working capital.
• Substantial additional funding is required; inability to raise capital when needed could force delays, reductions, or elimination of product development programs or cessation of operations.
• The engineered RedTail enveloped virus platform and allogeneic stem cell product candidates represent novel approaches, creating challenges related to manufacturing, immune-related adverse events (irAEs), and regulatory approval.
• Adverse publicity regarding viral-based or genetic therapies, particularly stem cell-based immunotherapy, could negatively impact business, public perception, and ability to raise capital.
• Preclinical studies and clinical trials may fail to demonstrate adequate safety and efficacy, leading to delays or prevention of regulatory approval and commercialization.
• Interim, top-line, and preliminary clinical trial data may change as more patient data become available, potentially differing materially from final results.
• Results of earlier studies and trials may not be predictive of future trial outcomes, and open-label study designs may exaggerate therapeutic effects.
• Difficulty in enrolling patients in clinical trials, especially for rare cancers like HGG, could delay or prevent regulatory approval.
• Even if approved, product candidates may not achieve broad market acceptance due to factors like efficacy, safety, cost, competition, and physician/patient willingness to adopt new therapies.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable, with no assurance of timely approval or favorable labeling.
• Changes in product manufacturing or formulation may result in additional costs or delays, including those related to scaling up to commercial production.
• Inadequate funding for regulatory agencies (FDA, SEC) or other disruptions could hinder their operations, impacting product review and approval timelines.
• Post-approval, products are subject to extensive and ongoing regulatory requirements, and non-compliance could lead to significant expenses, restrictions, or withdrawal of approval.
• Promotion of products for unapproved or off-label uses could lead to substantial fines, criminal penalties, and reputational harm.
• Competition from major pharmaceutical and biotechnology companies with greater resources poses a significant threat to the company's commercial opportunity.
• The company relies on third-party collaborators and contract manufacturers, and their failure to perform as expected could delay or impair product development and commercialization.
• Disputes with collaborators or licensors could arise, potentially affecting intellectual property rights or development timelines.
• The company's intellectual property protection is costly and difficult to maintain, with risks of infringement claims, invalidation of patents, and challenges from competitors.
• The company has insufficient cash to continue operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• The sale of additional common stock or other securities, including this offering, will result in significant dilution for existing shareholders and may depress the stock price.
• There is no public market for the Pre-Funded Warrants and Common Warrants, limiting their liquidity.
• The company's stock price may be volatile, and an active, liquid trading market for its common stock may not be sustained.
• Failure to comply with NYSE American listing standards could lead to delisting, impacting market value and liquidity.
• Changes in U.S. and international trade policies, including tariffs, could adversely impact business and operating results.
• Unstable global economic and geopolitical conditions, including military conflicts, could seriously affect business, financial condition, and stock price.

Future Outlook

The company anticipates advancing three clinical development programs over the next 6-24 months, including CLD-101 in a Phase 1 trial for recurrent HGG, CLD-201 in a Phase 1 trial for triple-negative breast cancer, HNSCC, and soft tissue sarcoma, and submitting an IND for its RedTail product candidate (CLD-401) for metastatic solid tumors by the end of 2026. The company expects to continue incurring significant and increasing operating losses for the foreseeable future as it advances its product candidates and operates as a public company. It will need substantial additional funding to support continuing operations and growth.

Management Comments

• Allan Camaisa's resignation as CEO and Chairman was not the result of any disagreement with the company or its Board or any matter relating to the company's operations, policies, or practices.
• The elimination of Dr. Boris Minev's position as President, Medical and Scientific Affairs, was part of an ongoing review of organizational structure and cost optimization efforts, and not due to any disagreement.
• Management believes that the net proceeds from this offering, together with existing cash and cash equivalents, will meet capital needs for the next 6 months under the current business plan, but substantial additional funding is required beyond that.

Industry Context

Calidi Biotherapeutics operates in the highly competitive and rapidly evolving immuno-oncology and genetic medicines space, specifically focusing on oncolytic viral therapies. While T-VEC is the only FDA-approved oncolytic virus therapy (for melanoma, intratumorally), Calidi's RedTail platform aims for systemic delivery to metastatic sites, representing a potential major advancement. The industry faces challenges with immune clearance of oncolytic viruses, which Calidi attempts to address with its enveloped virus and stem cell encapsulation approaches. The broader biotechnology sector is characterized by high capital intensity, lengthy development cycles, and significant regulatory hurdles, which Calidi also experiences. Recent legislative and regulatory proposals in the U.S. healthcare system, including drug pricing and diversity in clinical trials, could impact the industry and Calidi's operations.

Comparison to Industry Standards

• Calidi's approach with RedTail (systemic delivery of enveloped vaccinia virus) aims to overcome a major obstacle in oncolytic virotherapy, which is the rapid elimination of viruses by the patient's immune system, a challenge that has largely relegated existing therapies like Amgen's T-VEC (Imlygic) to local intratumoral delivery.
• The company's use of stem cells in SuperNova and NeuroNova platforms to protect oncolytic viruses from immune clearance and enhance viral amplification is a novel approach compared to traditional unprotected viral therapies.
• While T-VEC is a modified herpes simplex virus (HSV), Calidi's platforms utilize vaccinia virus and adenovirus, indicating a different viral vector strategy within the oncolytic virus field.
• The Fast Track Designation granted to CLD-201 by the FDA for soft tissue sarcoma aligns with industry efforts to expedite development for serious conditions with unmet medical needs, similar to designations sought by other biotech companies for their lead candidates.
• The company's reliance on third-party contract manufacturers (e.g., Genscript ProBio in China for CAL1 virus) and CROs is a common industry practice for clinical-stage biotechs that do not own their manufacturing facilities, but it introduces supply chain and quality control risks.
• The significant operating losses and accumulated deficit are typical for clinical-stage biotechnology companies that have not yet commercialized products, but the 'going concern' doubt highlights a more severe financial position compared to more established or better-funded peers.

Management Changes

Corporate Governance

Legal Proceedings

• A complaint was filed on November 15, 2023, by Tony Kalajian (prior Chief Accounting Officer and interim Chief Financial Officer) against the company, former CEO Allan Camaisa, and Chief Legal Officer Wendy Pizarro, alleging constructive discharge and defamation, seeking $0.6 million in damages, punitive damages, and attorneys' fees. The company denies the allegations and is seeking recovery of a $150,000 bonus Mr. Kalajian allegedly approved for himself without proper authorization.
• Mr. Kalajian filed a Petition for Writ of Mandate on February 29, 2024, seeking to compel production of corporate records, which was dismissed by stipulation in March 2025.
• Mr. Kalajian filed another complaint on May 1, 2024, alleging intentional conversion and violation of Delaware General Corporations Code due to the company's failure to remove a restrictive legend from 1,162 shares of his common stock, seeking compensatory and punitive damages.
• A lawsuit was filed by the company in July 2025 against a former executive assistant alleging breach of fiduciary duty and misappropriation/improper disclosure of confidential information, seeking injunctive relief and damages.
• A securities fraud complaint was filed on October 29, 2024, by Mr. Yian Zeng against the company, alleging securities fraud, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud. The company denies all claims, and a mandatory settlement conference in April 2025 resulted in no resolution.

Related Party Transactions

• As of June 30, 2025, $0.8 million in related party term notes payable (principal and accrued interest) were due to Directors A, classified as a short-term liability.
• Amounts owed to Director F (Allan Camaisa) for reimbursable expenses and to a relative of Officer A for legal fees were $21,000 as of June 30, 2025.
• The company is obligated to pay Allan Camaisa $500,000 in separation pay over 12 months and COBRA premiums for 12 months, commencing May 2025, as well as $10,000 per month in transition/consulting pay, and potential incentive payments based on revenues/capital received by December 31, 2026.
• A severance accrual and accrued interest of $0.4 million for former President and COO George K. Ng (Director D) was settled in January 2025.
• Accrued advisory fees of $18,000 were owed to Scott Leftwich (Director A) as of December 31, 2024, which were settled in January 2025.
• Allan Camaisa (Director F) provided a personal Guaranty of Lease up to $0.9 million for the San Diego Lease, for which the company agreed to pay him 10% of the Guaranty amount for the first year and 5% per annum thereafter, with amounts accrued and payable at lease termination or release from Guaranty. As of June 30, 2025, $4,000 was due, partially settled in April 2025.
• An agreement with Director A for deferred compensation and advisory fees of $0.5 million, bearing 14% interest, was paid in January 2025.
• Related party warrant liability of $7,000 as of June 30, 2025, and $9,000 as of December 31, 2024.
• A loan agreement with a relative of Officer A for $0.2 million, bearing 12% interest, was settled in full in January 2025.
• A strategic investment of approximately $2.0 million by a related-party accredited investor into Nova Cell (a subsidiary) in exchange for 25% of Nova Cell's fully-diluted capitalization occurred on July 26, 2024.

Stakeholder Impact

• **Shareholders:** Will experience immediate and substantial dilution from the current offering and any future capital raises. The 'going concern' doubt poses a significant risk to investment value. The reverse stock splits have also reduced the number of shares and may impact perception.
• **Employees:** Management changes, including the appointment of a new CEO and elimination of a President position, may affect organizational structure and morale. The company's financial instability could impact job security and future compensation.
• **Customers (Future):** The company's ability to bring novel cancer therapies to market depends on successful clinical trials and regulatory approvals, which are at risk due to funding constraints and inherent development challenges.
• **Suppliers/Creditors:** The 'going concern' doubt and recurring losses indicate potential risks for suppliers and creditors regarding timely payments and fulfillment of contractual obligations. The company's debt obligations are significant relative to its cash position.
• **Regulatory Bodies:** The company's compliance with FDA and SEC regulations is critical, and any failures could lead to penalties or delays in product development and commercialization.

Next Steps

• Advance CLD-101 in a Phase 1 clinical trial for recurrent High Grade Glioma (HGG).
• Advance CLD-201 in a Phase 1 clinical trial for triple negative breast cancer, head & neck squamous cell carcinoma (HNSCC), and soft tissue sarcoma.
• Submit an Investigational New Drug (IND) application to the FDA for the RedTail product candidate (CLD-401) for metastatic solid tumors by the end of 2026.
• Continue to pursue cost-efficient manufacturing processes for allogeneic stem cells.
• Explore and potentially enter into collaboration agreements for combination therapies using RedTail, SuperNova, and NeuroNova platforms.
• Pursue opportunistic out-licensing of stem cell-derived products.
• Raise substantial additional capital through public or private equity offerings and debt financings or other sources like collaboration agreements to fund operations beyond the next six months.
• Continue to defend against ongoing legal proceedings, including the complaint from the former Chief Accounting Officer and the securities fraud complaint.

Key Dates

Recommendation

Calidi Biotherapeutics is in a highly distressed financial state, evidenced by recurring significant losses, a substantial accumulated deficit, and an explicit 'going concern' warning from both management and its auditor. While the company is pursuing promising, albeit early-stage, clinical programs in a high-potential area (oncolytic virotherapy), its immediate liquidity is severely limited, with the current capital raise only projected to cover operations for six months. This necessitates continuous, highly dilutive financing activities, as demonstrated by multiple recent offerings and warrant exercises at reduced prices, and two reverse stock splits. The high degree of dilution, coupled with the inherent risks of clinical-stage biotech (e.g., trial failures, regulatory hurdles, intense competition), and ongoing legal challenges, makes the stock an extremely speculative and high-risk investment. The fundamental financial instability outweighs any potential long-term clinical upside at this juncture, making it unsuitable for most investors.

Keywords

Biotechnology, Oncology, Genetic Medicines, Oncolytic Viruses, RedTail Platform, SuperNova, NeuroNova, Clinical Stage, FDA Fast Track, Sarcoma Treatment, High Grade Glioma, Public Offering, Warrants, Dilution, Going Concern, SEC Filing, Biopharmaceutical, Cancer Therapy, Stem Cell Therapy, Reverse Stock Split